In fact, DPP-4 inhibitors are now replacing the use of sulphonylureas as insulin-releasing agents due to their insulin-tropic effect, and notably because DPP-4 inhibitors reduce the intrinsic risk of low blood sugar or hypoglycaemia. Here, DPP4 is linked to Hypoglycemia.